Impact of CEBPß depletion on enhancer responses to dexamethasone in Multiple Myeloma cells

Multiple myeloma (MM) is the second most common hematological cancer. While MM is considered treatable, it remains incurable due to the eventual drug resistance in nearly all patients. A cornerstone therapeutic for MM is dexamethasone, a synthetic glucocorticoid with anti-inflammatory and anti-myeloma properties. In this study, we investigate the role of CEBPß in modulating enhancer activities, measured by H3K27ac, in response to dexamethasone in MM cells. Overall design: Genome-wide profile of H3K27ac by Cut&Run in multiple myeloma cell line RPMI 8226 in DMSO control cells and CEBPB knockout cells, treated with or without dexamethasone (10um) for two hours.